focus -WSS

focus

author：hotspot 2025-10-04 04:00:31 - browse：2

WASHINGTON — Grail is aggressively lobbying to get Medicare to pay for its cancer-screening test Galleri — but experts tell STAT that the company has a far more complicated path to that end than the makers of most medicines or medical devices.

Grail’s controversial blood test Galleri screens for multiple cancers. The Food and Drug Administration has not yet approved it, so Medicare hasn’t had to make a decision on whether to cover it or not. Right now, most people pay for it out of pocket. It runs about $950.

In general, Medicare covers FDA-approved medicines and medical devices that help diagnose or treat disease or injury. But there’s a catch for Grail: Medicare doesn’t cover tests that simply screen healthy people, as Galleri does.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： ChatGPT in medicine: STAT answers readers' burning questions
Next article： Updated Covid vaccine has 54% effectiveness, new study suggests

WSS

Vyjuvek, a gene therapy for skin wounds, restored vision in one boy

Biotech companies concerned about China biosecurity crackdown

Readout LOUD: Venture capital, Gilead, and more M&A

Medical device lobby: We're tired of waiting on Medicare coverage

Why CTE doesn’t keep Americans from enjoying the Super Bowl

Readout Newsletter: Ironwood, Pfizer, FogPharma updates

explore

focus

hotspot

Jerome Adams on the need for new antivirals for Covid

AstraZeneca stays mum on Medicare drug pricing negotiations

Bright Health sells Medicare Advantage business to Molina

Padmanee Sharma of MD Anderson at center of lawsuit over credit

Duchenne breakthrough therapy leaves behind pioneering families

A protest over insulin prices is seen as a fight for life

How one medical school became remarkably diverse

Problems with a popular proposal to regulate AI in health care

Medicare proposal to cover medical devices draws a mixed reaction

Covid isolation guidance eased by the CDC

leisure time

Biotech companies concerned about China biosecurity crackdown

A protest over insulin prices is seen as a fight for life

A Q&A with Aletha Maybank, AMA’s chief health equity officer

Problems with a popular proposal to regulate AI in health care

How to fix the rural physician shortage in the U.S.

What’s missing from the debate over nursing home staff minimums

entertainment

entertainment

leisure time

hotspot